Breakout stocks
Query: Breakout stocks with relative volume > 1.2 · data as of 2026-10-12
Built a US stocks-only breakout screen with volume confirmation (relative volume > 1.2x) on active breakout/bullish-pattern signals, ranked by momentum potential. 8 names matched — led by EXEL, TWST, NVAX, SLAB, HUM, SNAP, ATEC and PBT — with columns for returns, relative volume, momentum potential, % from 150D SMA, proximity to 52-week high, technical setup, market cap, P/E and days since earnings, plus per-row qualitative commentary.
Breakout and bullish pattern setups with above-average volume (relative volume > 1.2x) as of October 12, 2026. Rows ranked by momentum potential. Health Care dominates the list, echoing the one-month rotation into medtech/biotech, alongside energy royalty and select tech.
Breakout Setups with Volume Confirmation
| Symbol | Company | Sector | Industry | Theme | 1D Return | 1M Return | 6M Return | Relative Volume | Momentum Potential | % from 150D SMA | % from 52W High | Technical Setup | Market Cap | P/E (TTM) | Days Since Earnings | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EXEL | Exelixis, Inc. | Health Care | Biotechnology | Oncology Therapeutics | -0.07% | 6.59% | 33.05% | 1.329 | 98.4 | 16.16% | -0.07% | Upward channel (46%) | 1.482e+10 | 18.81 | 67 | Cash-generative oncology name trading at a low-teens multiple with a fresh resistance break. Unlike most biotech breakouts this one is funded by approved-product revenue (Cabometyx franchise), so it is less exposed to the funding-market squeeze hitting development-stage peers. Watch for pipeline data and label-expansion catalysts rather than capital raises. |
| TWST | Twist Bioscience Corporation - Common Stock | Health Care | Diagnostics & Research | Life Science Tools & Reagents | -4.96% | 19.37% | 201.43% | 1.2324 | 91.3 | 62.33% | -25.92% | Upward channel (5%) | 1.007e+10 | — | 70 | Synthetic-biology tools maker that has been one of the strongest three-month moves in life-science tools, yet it is richly valued and loss-making — a classic high-beta beneficiary when the tools/reagents group is in favor. The pullback day on heavy volume inside a very steep advance is worth watching for a failure or a shakeout, and any move in DNA-synthesis demand or biopharma R&D budgets swings the story hard. |
| NVAX | Novavax, Inc. - Common Stock | Health Care | Biotechnology | Biopharma Drug Discovery Platforms | -0.71% | 34.39% | 56.10% | 1.4946 | 89.5 | 38.02% | -0.71% | Resistance breakout | 2.088e+09 | 4.91 | 67 | A rare biotech breaking out with actual product revenue and a single-digit earnings multiple. The setup sits at the 52-week high with volume confirmation, but the risk is binary seasonality in its vaccine franchise and thin margins; the move is more a re-rating of skepticism than a durable compounder story. |
| SLAB | Silicon Laboratories, Inc. | Information Technology | Semiconductors | Semiconductor Capital Equipment | -0.15% | 0.62% | 4.91% | 1.2274 | 80.1 | 2.38% | -0.49% | Upward channel (59%) | 7.397e+09 | — | 61 | Semiconductor name grinding higher in a tight upward channel near its highs. The relative strength stands out because it is bucking the weakness that hit the AI-hardware supply chain this month — a defensive, low-power/connectivity chip mix rather than a levered AI-capex play. Channel-resistance breaks tend to need a fundamental trigger to extend. |
| HUM | Humana Inc. | Health Care | Healthcare Plans | Property & Casualty Insurance | 0.38% | 5.78% | 119.20% | 1.3178 | 75.9 | 34.28% | 0.00% | Resistance breakout | 5.205e+10 | 40.97 | 75 | Managed-care breakout pressing the 52-week high with strong volume — a beneficiary of the defensive rotation into Health Care while the rest of the market de-grosses. The risk is entirely policy/rate-driven: any move on Medicare Advantage reimbursement or medical-cost trend can reverse the trend fast, and the valuation already reflects a big recovery in the earnings trajectory. |
| SNAP | Snap Inc. | Communication Services | Internet Content & Information | Ad-Tech & Digital Advertising, Social Media Platforms | 4.82% | 14.96% | 26.80% | 1.2639 | 59.6 | 24.18% | -28.16% | Resistance breakout | 1.104e+10 | — | 69 | Ad-dependent social platform breaking out on heavy volume even as the broader momentum complex gets sold. Its small price and depressed multiple make it a high-beta, event-driven name rather than a quality holding; sustained upside depends on ad-pricing/monetization execution and ad-market health, both of which remain the swing factor. |
| ATEC | Alphatec Holdings, Inc. | Health Care | Medical Devices | Medical Devices & Surgical Technologies | 5.44% | 6.33% | 0.00% | 1.352 | 37.3 | 16.48% | -50.40% | Resistance breakout | 1.738e+09 | — | 68 | Small-cap spine/medtech name breaking out with volume, riding the medtech group's relative strength, but still well below its prior highs — a deep recovery play rather than a new-high leader. Thin profitability and a heavy debt load amplify the risk if procedure volumes or reimbursement tighten. |
| PBT | Permian Basin Royalty Trust Common Stock | Energy | Oil & Gas Midstream | Oil & Gas Royalty & Land | 2.27% | 0.63% | 63.25% | 1.3059 | — | 27.67% | -1.27% | Upward channel (37%) | 1.563e+09 | — | — | Oil & gas royalty trust: a pure cash-distribution vehicle tied to Permian production, so the breakout is really a leveraged bet on crude and natural-gas realizations. Trusts deplete over time and distributions fall with production and commodity prices — treat this as an income/momentum trade with commodity-capex risk, not a growth story. |
Run a version of this yourself
Describe the idea in plain English and Relaxfolio returns a researchable shortlist with the charts, fundamentals, and risks attached.
Educational research tool — not investment advice. A screen is a starting point, not a recommendation.